Perineural Injection and Supraspinatus Tendenopathy
Supraspinatus Tendinopathy
About this trial
This is an interventional treatment trial for Supraspinatus Tendinopathy
Eligibility Criteria
Inclusion Criteria:
Patients with supraspinatous tendinopathy
Exclusion Criteria:
-Shoulder joint instability omplete rotator cuff tear Adhesive capsulitis Septic arthritis Malignancy Coagulopathy Connective tissue diseases Spondyloarthropathies Previous corticosteroid injection in the last six months. Previous other forms of regenerative injection therapy (e.g prp injection therapy) in the last six mo
Sites / Locations
- Reham Magdy ShaatRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
perineural injection group
deepprolotherapy group
perineural injection therapy group (subcutaneous prolotherapy) This group included 30 patients aged from 18 to 60 years Buffered glucose preparation : 2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection sessions at sites of chronic constriction injurey of the following nerves : Suprascapular nerve..
Deep prolotherapy injection group The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine. The pathological area of the supraspinatous tendon was identified and graded using ultrasound pathology rating scale guided by ultrasonography (Simens Acuson p300 machine) Proper preparation with antiseptic solution of skin overlying the point of injection .